Menveo
Menveo Uses, Dosage, Side Effects, Food Interaction and all others data.
Presence of bacteriocidal anti-capsular meningococcal antibodies associated with protection from invasive meningococcal disease.
Meningococcal serogroup A, C, Y and W-l 35 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier.
Induces production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-l 35.
| Trade Name | Menveo |
| Generic | Meningococcal group A Diphtheria Conjugate Vaccine |
| Weight | 200mcg/0.5ml, , polysaccharidetetanustoxoidgroupacyw |
| Type | Injection, Intramuscular Powder For Injection, Intramuscular Solution |
| Therapeutic Class | Vaccines, Anti-sera & Immunoglobulin |
| Manufacturer | Renata Limited, Novartis Pharma (pak) Ltd |
| Available Country | Bangladesh, Canada, Pakistan, Australia, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Meningococcal infection
Dosage
Menveo dosage
The dosing schedule for individuals initiating vaccination is as follows:
Infants: 2 Months of Age: administered as a four-dose series at 2,4, 6, and 12 months of age.
Children: 7 Months through 23 Months of Age: administered as a two-dose series with the second dose administered in the second year of life and at least three months after the first dose.
Children: 2 Years through 10 Years of Age: administered as a single dose. For children 2 years through 5 years of age at continued high risk of meningococcal disease, a second dose may be administered 2 months after the first dose.
Adolescents and Adults: 11 Years through 55 Years of Age: administered as a single dose.
Side Effects
Common solicited adverse reactions (>10%) among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness (24-41%) and erythema at injection site (11-15%), irritability (42-57%), sleepiness (29-50%), persistent crying (21-41 %), change in eating habits (17-23%), vomiting (5-11%) and diarrhea (8-16%).
Common solicited adverse reactions (>10%) among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness (10-16%) and erythema at injection site (12-15%), irritability (27-40%), sleepiness (17-29%), persistent crying (12-21%), change in eating habits (12-20%) and diarrhea (10-16%).
Common solicited adverse reactions (>10%) among children 2 years through 10 years of age who received injection site pain (31%), erythema (23%), irritability (18%), induration (16%), sleepiness (14%), malaise (12%), and headache (11%). Common solicited adverse reactions (>10%) among adolescents and adults who received were pain at the injection site (41%), headache (30%), myalgia (18%), malaise (16%) and nausea (10%).
Precaution
Guillain-Barre syndrome. Preventing & managing allergic vaccine reactions. Thrombocytopenia or bleeding disorders. Immunocompromised person. Pregnancy & lactation.
Interaction
Live vaccines. Reduced immunological response with immunosuppresants.
Pregnancy & Breastfeeding use
Pregnancy Category-C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Contraindication
Severe allergic reaction (e.g., anaphylaxis) after a previous dose , any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine is a contraindication to administration
Innovators Monograph
You find simplified version here Menveo
